作者: Fabio Fumagalli , Angelisa Frasca , Giorgio Racagni , Marco Andrea Riva
DOI: 10.2165/00023210-200923070-00005
关键词: Prefrontal cortex 、 Neuroscience 、 Cognition 、 Neurochemical 、 Hippocampus 、 Atypical antipsychotic 、 Schizophrenia 、 Neuroplasticity 、 Psychopharmacology 、 Psychology
摘要: Historically, pharmacotherapy for schizophrenia was mainly focused on finding drugs to treat psychotic symptoms only, without addressing other crucial domains of the disorder such as cognitive impairments. As a result, these have remained undertreated. In this review, we discuss recent preclinical research efforts, including investigation synaptic mechanisms well intracellular signalling pathways and involved in neuroplasticity cell resilience, that may represent new participating pathogenesis schizophrenia, particularly at level prefrontal cortex hippocampus, might lead development can counteract, least partially, impairments typical schizophrenia.